Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 7/20 | 0.38 |
| ▸ | NNMT | P40261 | 3/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | AMPD3 | Q01432 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21783073 | 0.86 | CRBN (0.41) | VNN1NNMTCRBNRXRARXRB | |
| SCHEMBL21783039 | 0.80 | NNMT (0.42) | NNMTHCAR2CRBNRXRARXRB | |
| SCHEMBL21783035 | 0.78 | NNMT (0.45) | NNMTCRBNRXRARXRBRXRG | |
| SCHEMBL21783047 | 0.76 | NNMT (0.39) | NNMTHCAR2CRBNRXRARXRB | |
| SCHEMBL21772873 | 0.75 | OPRM1 (0.38) | NNMTCRBNKDM4E | |
| SCHEMBL30903477 | 0.75 | OPRM1 (0.38) | NNMTCRBNKDM4E | |
| SCHEMBL21783076 | 0.73 | MGAM (0.39) | VNN1NNMTCRBNKDM4EMAPT | |
| SCHEMBL30903482 | 0.73 | VNN1 (0.50) | VNN1 | |
| SCHEMBL30903481 | 0.73 | VNN1 (0.50) | VNN1 | |
| SCHEMBL21772931 | 0.72 | NNMT (0.38) | NNMTHCAR2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-04 | — | — | US | disclosed |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-15 | — | — | US | disclosed |
| WO-2020043658-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-03-05 | — | — | WO | disclosed |
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069663-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | VNN1 23/4885NNMT 2142/4885HCAR2 929/4885 |
| US-20210059992-A1 | HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS | VHL, FANCI, PAH | VNN1 23/4885NNMT 2142/4885HCAR2 929/4885 |
| US-10864201-B2 | Heteroaromatic compounds as Vanin inhibitors | VHL, FANCI, PAH | VNN1 23/4885NNMT 2142/4885HCAR2 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.